The Wacky World of Diabetes

At the end of the day what needs to be brought to the marketplace are solutions to problems that consumers face. Val Asbury, CEO of LifeScan, is on a mission to do just that. LifeScan is the maker of One Touch, and Val navigates all its business and operations, which operates around the world with more than 2,000 employees. Her background in nursing and extensive general management experience has been vital in playing a role in the success of her diverse range of leadership, along with an undying passion for ‘meaningful' healthcare. Let's get right into the episode and learn from Val how LifeScan is creating a global ecosystem to support meaningful healthcare.  [00:01 - 02:18] Opening Segment I introduce Val Asbury Val shares his background and story Nurse by training  A passion for meaningful healthcare  Journey into deep diabetes  [02:19 - 14:01] Giving Patients the Ability to Customize Their Wellness Val explains the journey behind the start of competitive bidding  What was meant to create choice limited it From a fortune 500 to a private equity The slow processes of a fortune 500  More freedom to move quick under a private equity  Keeping the mission front and center  Val shares her thoughts on the new world of subscription models  The evolution is the most important  People are diverse, they should have options Val talks about the strategy behind her partnerships  The goal is consulting Going beyond just glucose management  CGM coming soon Bringing in industry leaders to tailor solutions  Soon to launch: consumer portal  [14:02 - 22:58] Creating a Global Ecosystem of Meaningful Healthcare How LifeScan is overcoming the competition  A focus on the core business  Strategic partnerships with industry leaders A global vision  Data from internal systems as well as partners  Val talks about the differences in procedures in different countries  LifeScan and insulin delivery  The move into digital tools  A surprising but needed evolution  What patients want Are we solving their problems? [22:59 - 25:32] Closing Segment A change in payer priorities  What's next for Val  LifeScan for the long term How to connect with Val Links below  Final Words  Tweetable Quotes: “If you run a responsible business and you do the right things to support the business, what I'm finding… is we have a lot more latitude and speed to be able to bring solutions into the marketplace.” - Val Asbury “We'll have so much diversity of the data that we should be able to correlate and talk to people about their health and what combinations work well… and all make a meaningful difference overtime.” - Val Asbury  Connect with Val by checking out https://www.lifescan.com/ (https://www.lifescan.com/) and take action to support a life of wellness. To know more, you can connect with me, David Kliff onhttps://www.linkedin.com/in/ephraim-glick-8403a465/ ( )https://www.facebook.com/DiabeticInvestor/ (Facebook), https://twitter.com/diabetic_invstr?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor (Twitter), and https://www.linkedin.com/in/david-kliff-78b669b/ (LinkedIn), or email me at dkliff@diabeticinvestor.com. Be sure to visit https://diabeticinvestor.com (https://diabeticinvestor.com) for more insights and real-time analyses on the evolving business of diabetes. Don't be shy, I'd love to hear from you! You can also reach me at 224-715-3761. NOTE*: We are in no way a replacement for real medical professionals. All information in this podcast is obtained through reliable sources. Please be aware of our https://diabeticinvestor.com/investment-newsletter-disclaimer/ (Disclaimer). LEAVE, SUBSCRIBE, REVIEW + help someone who wants to learn more about the wacky world of diabetes and everything happening within it.

There is a lot happening in insulin sales that are providing benefits; it's just that most patients aren't the ones seeing those benefits. Scott Strumello is a consultant, writer, speaker and advocate with those living with T1D. Scott is passionate about getting real information to people by diving into medical data and scientific literature before drawing any conclusions. His ‘no-nonsense' approach to facts-based reporting has led him to become an authority on all things diabetes investment with a dedicated following on social media.  Jump into the episode and join us for a Scott's perspective on the business of insulin. [00:01 - 02:52] Opening Segment I introduce Scott Strumello  Scott shares his background and story Diagnosed at age 7  Becoming active in the diabetes space  The ‘business of diabetes'  [02:53 - 15:59] A No-Nonsense Perspective on the Business of Insulin Scott talks about his current diabetes management  Scott's thoughts on state legislation  The effects of Price Caps The rebate mess  A look into the GLP1 space  Watching it for trends Scott shares about his audience An organic growth process  Personal view on insulin  Underwhelmed by the G6 [16:00 - 28:01] Reimagining Insulin Legislation  How Scott engages with opposition  Scott's view on apps  Why most suck  How Scott would do the legislation around insulin  Transparency and pass through  [28:02 - 30:35] Closing Segment How to connect with Scott  Links below  Final Words  Tweetable Quotes: “I find that a lot of apps are developed, particularly by third party developers… I find most of those apps suck… they are solutions in search of a problem to solve.” - Scott Strumello  “I think, first of all, transparency is valuable, but transparency alone isn't going to ‘fix it' for patients… Second of all, I think full pass-through of rebates to patients at the point of sale.” - Scott Strumello “I think most insulin is competed on for price, it's just that most patients don't get the benefit of it.” - Scott Strumello  Connect with Scott on https://twitter.com/sstrumello (Twitter). Be sure to check out http://blog.sstrumello.com/ (http://blog.sstrumello.com/) if you want to be up to date with all the latest in Diabetes.  To know more, you can connect with me, David Kliff onhttps://www.linkedin.com/in/ephraim-glick-8403a465/ ( )https://www.facebook.com/DiabeticInvestor/ (Facebook), https://twitter.com/diabetic_invstr?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor (Twitter), and https://www.linkedin.com/in/david-kliff-78b669b/ (LinkedIn), or email me at dkliff@diabeticinvestor.com. Be sure to visit https://diabeticinvestor.com (https://diabeticinvestor.com) for more insights and real-time analyses on the evolving business of diabetes. Don't be shy, I'd love to hear from you! You can also reach me at 224-715-3761. NOTE*: We are in no way a replacement for real medical professionals. All information in this podcast is obtained through reliable sources. Please be aware of our https://diabeticinvestor.com/investment-newsletter-disclaimer/ (Disclaimer). LEAVE, SUBSCRIBE, REVIEW + help someone who wants to learn more about the wacky world of diabetes and everything happening within it.

A diagnosis is not the end, you can still live life to the fullest even with diabetes. Caitlin Grenier is the Founder of Party Like a Diabetic, and is introducing the ultimate health and wellness program that will help you and your patients decrease stress, increase self-esteem, and stabilize blood sugars while living an empowered life. She does this by creating real-world solutions that break the traditional ways of diabetes management that just don't seem to work. I'm so excited for this episode to give you a ton of value as Caitlin tells us more about her story, Party Like a Diabetic as well as managing, not only diabetes, but the diagnosis itself. [00:01 - 03:09] Opening Segment I introduce Caitlin Grenier  Caitlin shares her background and story How we met  How Caitlin was diagnosed  [03:10 - 10:14] Party Like a Diabetic: Don't Go Through A Diagnosis Alone What is Party Like a Diabetic Book crossed with a journal  Links below  Caitlin's management  Injections  CGM changes the game  Why Libre opposed to Dexcom Reactions to Caitlin's diagnosis A progression of letting people in  [10:15 - 14:41] Living a Full Life with Diabetes  Why not the pump at first?   Getting comfortable and understanding the body The wireless trend  The goal of Party Like a Diabetic  You can live a full, empowered life Living without the definition  [14:42 - 16:15] Closing Segment What's next for Caitlin  More books  New approaches to diabetes management  How to connect with Caitlin and her work  Links below  Final Words  Tweetable Quotes: “I felt so lost, so frustrated, so confused, and really didn't know where to turn… I decided I didn't want anybody to feel like that again… and Party Like a Diabetic came about.” - Caitlin Grenier “You can still live a full, empowered life with diabetes. It doesn't have to stop you, it doesn't have to inhibit you.” - Caitlin Grenier  Resources Mentioned:  https://www.amazon.com/Sweet-Journal-Develop-Happiness-Muscle/dp/1543276490 (Sweet Ass Journal) https://doingitthreeways.com/ (Doing It Three Ways: Race) https://www.lavamantriathlon.com/ (Lavaman) Connect with Caitlin on https://www.linkedin.com/in/women-health-wellness-diabetes-coach-entrepreneur/ (Linkedin), https://www.instagram.com/partylikeadiabetic/?hl=en (Instagram), and https://www.facebook.com/caitlin.grenier.7 (Facebook). Check out https://partylikeadiabetic.co/ (https://partylikeadiabetic.co/) and grab the journal for yourself. To know more, you can connect with me, David Kliff onhttps://www.linkedin.com/in/ephraim-glick-8403a465/ ( )https://www.facebook.com/DiabeticInvestor/ (Facebook), https://twitter.com/diabetic_invstr?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor (Twitter), and https://www.linkedin.com/in/david-kliff-78b669b/ (LinkedIn), or email me at dkliff@diabeticinvestor.com. Be sure to visit https://diabeticinvestor.com (https://diabeticinvestor.com) for more insights and real-time analyses on the evolving business of diabetes. Don't be shy, I'd love to hear from you! You can also reach me at 224-715-3761. NOTE*: We are in no way a replacement for real medical professionals. All information in this podcast is obtained through reliable sources. Please be aware of our https://diabeticinvestor.com/investment-newsletter-disclaimer/ (Disclaimer). LEAVE, SUBSCRIBE, REVIEW + help someone who wants to learn more about the wacky world of diabetes and everything happening within it.

With the rise in digital diabetes health, with all it's benefits, many feel we are still missing out on the human element. David Weingard is changing that. David is the Founder of Cecelia Health (formerly Fit4D), whose mission is to improve the lives of people living with diabetes and other chronic diseases throughout the world. The company is dedicated in honor and memory of Cecelia Bourne-Cort, who helped David rebuild his life after his diagnosis with Type 1 diabetes.  Dive in and learn how David is creating a platform with paying clients looking to succeed in bringing human connection to digital health.  [00:01 - 05:38] Opening Segment I introduce David G. Weingard David shares his background and story David's diabetes journey  The story behind of Cecelia Health  David's management and regiment after getting diagnosed Insulin pumps at first The tracking process David's CGM experience [04:39 - 13:12] Bringing Human Connection to Digital Health  David talks about his work with Cecelia  Two groups of clients  The way Cecelia helps people personally  How Cecelia is human driven  The usability  The use of expert clinicians  Improving outcomes through engagement  How they manage engagement  Segmentation of the population Finding out what they need  Key partnerships  Benefits of the Lifescan partnership [13:13 - 17:52] What Investors Need to Understand Investor misconceptions about the digital space  People think the app is the solution  Understanding of the magnitude  The need for telemedicine  What's next for Cecelia The virtual flavor Diabetes health care and mental health  The ability for medication adjustments  How they plan to grow  Current stance and expectations [17:53 - 29:02] Closing Segment The impact of at-risk-contracting How Cecelia's health plans work  Positive demonstrations and metrics Sensitive to app fatigue  Final Words  Tweetable Quotes: “What we do that's different… We leverage an expert diabetes clinician, clinicians who really understand their devices, who really understand diabetes and of course their nurses, dietitians, or pharmacists; and they proactively reach out to patients.” - David G. Weingard “For us it's all about growth now… It's all about - how much can we scale to help people as fast as we can?” - David G. Weingard Resources Mentioned:  https://www.lifescan.com/ (Lifescan) Connect with David on https://www.linkedin.com/in/davidweingard/ (LinkedIn). Check out https://www.ceceliahealth.com/ (https://www.ceceliahealth.com/) to learn more about a flexible approach to a chronic condition.   To know more, you can connect with me, David Kliff onhttps://www.linkedin.com/in/ephraim-glick-8403a465/ ( )https://www.facebook.com/DiabeticInvestor/ (Facebook), https://twitter.com/diabetic_invstr?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor (Twitter), and https://www.linkedin.com/in/david-kliff-78b669b/ (LinkedIn), or email me at dkliff@diabeticinvestor.com. Be sure to visit https://diabeticinvestor.com (https://diabeticinvestor.com) for more insights and real-time analyses on the evolving business of diabetes. Don't be shy, I'd love to hear from you! You can also reach me at 224-715-3761. NOTE*: We are in no way a replacement for real medical professionals. All information in this podcast is obtained through reliable sources. Please be aware of our https://diabeticinvestor.com/investment-newsletter-disclaimer/ (Disclaimer). LEAVE, SUBSCRIBE, REVIEW + help someone who wants to learn more about the wacky world of diabetes and everything happening within it.

It's time to give patients a chance to do something different to gain control of their disease. Michael Castagna is the CEO of MannKind, the company on the - “cutting edge of helping transform the care of diabetes where people can really get real-time control.” Michael is an entrepreneurial executive with more than 20 years of experience in the strategic development in Fortune 500 companies as well as privately held biotech start-ups. His innovation is driven by a mission to develop the products and therapies that can help people take control of their health and experience the best of what life has to offer. Let's dive right into this episode where you'll learn how Afrezza hit the market, how it's changing the speed of the ‘in and out' of insulin, how it all works, and how it may just be the future of insulin. [00:01 - 05:36] Opening Segment I introduce Michael Castagna Michael shares his background and story Journey and success in the pharmaceutical world  The approval of Afrezza  [05:37 - 13:53] The Fastest Acting Insulin on the Market Michael shares the touch and go process of Afrezza  Mistake made along the way Investing his own money  Getting back on track Explaining the inner workings of Afrezza  Human insulin  Fast acting  How it gets out of the body Following the pediatrics  Green light to phase 3 [13:54 - 25:16] Impacting Mankind with MannKind Partnerships with doctors The ones who understand take it on board  Michael talks about the transition process of MannKind Royalties  Pipeline  Technology  Current numbers Michael looks out to the next 5 years of MannKind and Afrezza Thoughts on acquisitions  Organic growth and shareholder value  Afrezza as a global product  Launching the next drugs [25:17 - 29:02] Closing Segment The future of Insulin Michaels final message to listeners  You have nothing to lose  Try a new tool and get to know it Think about your patients  Final Words  Tweetable Quotes: “I liked running into the fires and fixing things…” - Michael Castagna “It works fast, it works completely different from injectable insulin… It's in and out of the body quickly.” - Michael Castagna “Why not try a whole new tool…? We're going to be here for the next 20 years. Your patients want to try this. Give them a chance to do something different to gain control of their disease.” - Michael Castagna Resources Mentioned:  https://afrezza.com/ (Afrezza) Connect with Michael on https://twitter.com/mannkindcorp/status/983794225039880192?lang=en (Twitter), https://www.linkedin.com/in/michael-castagna-a15770/ (LinkedIn), and https://www.facebook.com/MannKindCorp/posts/michael-castagna-ceo-of-mannkind-believes-were-on-the-cutting-edge-of-helping-tr/10156426077168629/ (Facebook). Go check out https://mannkindcorp.com/ (https://mannkindcorp.com/) a learn more about how they are making life more human! To know more, you can connect with me, David Kliff onhttps://www.linkedin.com/in/ephraim-glick-8403a465/ ( )https://www.facebook.com/DiabeticInvestor/ (Facebook), https://twitter.com/diabetic_invstr?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor (Twitter), and https://www.linkedin.com/in/david-kliff-78b669b/ (LinkedIn), or email me at dkliff@diabeticinvestor.com. Be sure to visit https://diabeticinvestor.com (https://diabeticinvestor.com) for more insights and real-time analyses on the evolving business of diabetes. Don't be shy, I'd love to hear from you! You can also reach me at 224-715-3761. NOTE*: We are in no way a replacement for real medical professionals. All information in this podcast is obtained through reliable sources. Please be aware of our https://diabeticinvestor.com/investment-newsletter-disclaimer/ (Disclaimer). LEAVE, SUBSCRIBE, REVIEW + help someone who wants to learn more about the wacky world of...

The internet is bringing people together like never before. Amy Tenderich is a journalist, blogger, and nationally known patient advocate. She hosts a series of diabetes innovation leadership events, and is a frequent public speaker on diabetes and digital health topics and is also the Co-author of the book, "Know Your Numbers, Outlive Your Diabetes." Since Amy launched DiabetesMine.com, it's become one of the Top Health Blogs in the country and worldwide and has joined Healthline Media to create summits and forums to help bring people together. Don't miss out on this conversation, jump in and learn more about how Amy's work has led to patient advocacy. [00:01 - 06:41] Opening Segment I introduce Amy Tenderich Amy shares her background and story Becoming an advocate for patients as a patient  The growth of DiabetesMine Innovating diabetes tech early on Launching events and forums to bring people together [06:42 - 16:31] The Growing Interactions Between Diabetes and Social Media Amy talks about the changes from then vs. now From exciting peer support to something taken for granted A growing sense of anger and feeling of exploitation The social media activity between T1D and T2D A growing voice  Findings from research  How to deal with misinformation and abuse  Moderations  Two-way communication  The problems of comparison How Amy navigates consumer and client requests  [16:32 - 23:44]  Amy's views on ‘digital diabetes' The evolution of our world Top things consumers say change their life CGM is the number one thing A mix of online resources and community  Looping systems and online appointments  How different demographics respond to diagnosis  Are vendors getting it?  What people want vs. practicality  [23:45 - 31:07] Closing Segment What's next for Amy and DiabetesMine? Using strengths to advocate for the community  Future events and forums  Helping people feel represented  Organizations attempting to respond to criticism  Projecting 7 years into the future  Final Words  Tweetable Quotes: “A lot of people who thought that they would not like to have online doctors appointments have actually found that it's really convenient and they often get just as good attention from their doctors, sometimes maybe even better.” - Amy Tenderich “People want to do the least possible for their diabetes and get the best possible outcomes.” - Amy Tenderich  Resources Mentioned:  https://www.amazon.com/Numbers-Outlive-Diabetes-Marlowe-Library/dp/1569242720 (Know Your Numbers, Outlive Your Diabetes) Connect with Amy on https://twitter.com/amydbmine?lang=en (Twitter), https://www.linkedin.com/in/amytenderich/ (LinkedIn), and https://www.facebook.com/amy.tenderich (Facebook). Go check out https://www.healthline.com/diabetesmine (https://www.healthline.com/diabetesmine) to learn more about their innovations in Diabetes. To know more, you can connect with me, David Kliff onhttps://www.linkedin.com/in/ephraim-glick-8403a465/ ( )https://www.facebook.com/DiabeticInvestor/ (Facebook), https://twitter.com/diabetic_invstr?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor (Twitter), and https://www.linkedin.com/in/david-kliff-78b669b/ (LinkedIn), or email me at dkliff@diabeticinvestor.com. Be sure to visit https://diabeticinvestor.com (https://diabeticinvestor.com) for more insights and real-time analyses on the evolving business of diabetes. Don't be shy, I'd love to hear from you! You can also reach me at 224-715-3761. NOTE*: We are in no way a replacement for real medical professionals. All information in this podcast is obtained through reliable sources. Please be aware of our https://diabeticinvestor.com/investment-newsletter-disclaimer/ (Disclaimer). LEAVE, SUBSCRIBE, REVIEW + help someone who wants to learn more about the wacky...

Today I have the pleasure of sitting down with the Diabeloop crew. Diabeloop has been involving people living with Type 1 diabetes and their families and has contributed to the development alongside engineers and healthcare professionals. The focus is on ease of use and intuitive interfaces that are inspired by users themselves.  I can't wait to get started and learn how they are revolutionizing the future of diabetes through their complex algorithm that provides a simple user experience. [00:01 - 04:25] Opening Segment I introduce the Diabloop crew Eric shares his background  How Diabeloop works Comparing and contrasting Interaction and tuning Giving users choice [04:26 - 13:04]  Unique Algorithm and Strategic Partnerships Eric explains the algorithm  Taking into account lifestyle and physiology as a whole Strategic deals Diabeloop has made The Roche deal Helping the transition to get something in people's hands Complementary deal with Roche and Biocorp Eric's thoughts on the commoditization of closed loop algorithms The algorithm should work with what we have [13:05 - 25:20] Complicated Algorithm, Simple User Experience  The importance of a simple user experience Different algorithms developing - 5 year projection  Algorithms will advance How Diabeloop makes money Selling a monthly subscription for the algorithm  Reimbursement How to bring this to US Must have FDA approval Distribution partnerships From Diabeloop to doctor to patient Why you should go with Diabeloop The algorithm gets smarter as you where it Zen mode [25:21 - 29:48] Closing Segment How Diabeloop is going to change the future The power of choice Becoming less intensively managed  Testimonial  Shacey's projections on insulin Exciting things in the pipeline The dynamics of running a public company Play to win not to survive Technology is outpacing the health machine complex We're all in this together The introduction of utilizing people's information Final Words  Tweetable Quotes: “Some people want to be able to have as fine tuned control as possible… You can't separate physiology and lifestyle.” - Eric Honaker, Diabeloop Connect with Diabeloop on https://twitter.com/diabeloop?lang=en (Twitter). Go check out https://www.diabeloop.com/ (https://www.diabeloop.com/)  To know more, you can connect with me, David Kliff onhttps://www.linkedin.com/in/ephraim-glick-8403a465/ ( )https://www.facebook.com/DiabeticInvestor/ (Facebook), https://twitter.com/diabetic_invstr?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor (Twitter), and https://www.linkedin.com/in/david-kliff-78b669b/ (LinkedIn), or email me at dkliff@diabeticinvestor.com. Be sure to visit https://diabeticinvestor.com (https://diabeticinvestor.com) for more insights and real-time analyses on the evolving business of diabetes. Don't be shy, I'd love to hear from you! You can also reach me at 224-715-3761. NOTE*: We are in no way a replacement for real medical professionals. All information in this podcast is obtained through reliable sources. Please be aware of our https://diabeticinvestor.com/investment-newsletter-disclaimer/ (Disclaimer). LEAVE, SUBSCRIBE, REVIEW + help someone who wants to learn more about the wacky world of diabetes and everything happening within it. 

There is new, winning technology coming to the market that is easier to use than a smartphone, adaptive, completely wireless, and fully controllable by users. Shacey Petrovic is the CEO of Insulet, an innovative medical device company making the lives of people with diabetes easier through the use of its Omnipod product platform. Shacey has a strong background in med tech and life sciences, but also takes the diabetes market by storm with her skills in commercial leadership, sales, marketing, and 'put the patient first' mentality. An incredible individual, I can't wait for us to dive in and learn from Shacey how she is bringing innovation to the market with tubeless Omnipod technology. [00:01 - 03:15] Opening Segment I introduce Shacey  Shacey's background and experience Med tech and business background  Working in women's health  Recruited to Insulet  Synergies between diabetes and women's health care The challenges and rewards The shock of industry dynamics drive rather than patient welfare [03:16 - 15:20]  Bringing Innovation to the Market with Tubeless Omnipod Technology Differences from the conventional insulin pump model Getting better outcomes for patients Why so many are converting to MDI Better control  Reducing burden  Great to be wireless/tubeless  Shacey talks about the Omnipod 5 and its features  What makes it transformative  The first tubeless insulin delivery Controlled via smartphone  Adaptive features  FDA support Forward leaning with diabetes innovation  Shacey's thoughts on prefilled cartridge delivery  [15:21 - 23:58] How Omnipod 5 Navigates the Digital Market Shacey talks about Insulet and the Insulin industry Getting people broader access  Reducing burden for users  Thoughts on entering the Amazon marketplace The benefit of working with co-pays over deductibles  Predictable and affordable  Shacey shares about the drug delivery system Strategic partnerships  A wave of innovation in the market Navigating the new challenges in the market Telehealth and virtual training  Balancing in-person with at-home How Omnipod 5 takes on the new challenges [23:59 - 29:48] Closing Segment Let's talk five to seven years out  The launch of Omnipod 5 CGM data in the works Only simple and effective solutions Shacey's projections on insulin Exciting things in the pipeline The dynamics of running a public company Play to win not to survive Technology is outpacing the health machine complex We're all in this together The introduction of utilizing people's information Final Words  Tweetable Quotes: “All of our users and what my team is excited about is that this will really leapfrog the market. It will be the first fully wearable, wireless or ‘tubeless' automated insulin delivery.” - Shacey Petrovic “Everybody wants better control, but most people don't want to work harder. So if we can help them get better control without having to work hard for it, that's a winning combination.” - Shacey Petrovic “There's this innovation and technology adoption wave happening in diabetes, and we're investing to capture that.” - Shacey Petrovic Connect with Shacey on https://www.linkedin.com/in/shaceypetrovic/ (LinkedIn). Go check out https://insulet.com/ (https://insulet.com/) and learn more about their groundbreaking insulin management technology. To know more, you can connect with me, David Kliff onhttps://www.linkedin.com/in/ephraim-glick-8403a465/ ( )https://www.facebook.com/DiabeticInvestor/ (Facebook), https://twitter.com/diabetic_invstr?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor (Twitter), and https://www.linkedin.com/in/david-kliff-78b669b/ (LinkedIn), or email me at dkliff@diabeticinvestor.com. Be sure to visit https://diabeticinvestor.com (https://diabeticinvestor.com) for more insights and real-time

At the end of the day, the businesses that matter are the ones that are helping people take back their lives by not letting a diagnosis hold them back. Jeff Dachis is CEO and Founder ONE DROP, a business doing just that by helping people navigate chronic health conditions together, ‘One Drop' at a time. With over 20 years driving digital transformation and change, Jeff has a proven track record in envisioning new market opportunities, innovating new solutions, and strategizing competitive positions. Let's dive right into Jeff's insights about diabetes technology and learn what ‘precision health' is all about and how it's taking the market by storm. [00:01 - 05:50] Opening Segment I introduce Jeff Dachis Jeff's background and diabetes experience CEO of One Drop Inspired by his own diagnosis What is One Drop: Bringing people ‘precision health' What it offers that no one else does Data and science driven [05:51 - 11:21]  Storming the Market with Strategic Partnerships Jeff talks about his current work with Bayer Partnering with One Drop Bayer's vision to move beyond pills How One Drop Makes money Bringing the platform to the market Direct to consumer sales Partnering with digital retailers Building a good relationship with Dexcom Seamless flow of data Bringing insights that lead to better choices Jeff shares about moving passed CGM Technology Moving towards ‘precision health' [11:22 - 21:42] Bringing 'Precision Health' to the Market Jeff talks about his current customer base 50% opt in for multiple condition approach People want to monitor everything at all times Whole Person based solutions T1D vs.Type 2 client base Prioritizing meeting the needs of people People are complex, not just patients Jeff's thoughts on Amazon and Apple entering the Digital Diabetes space The consumerization of health and wellness Consumer side vs. medical  Jeff's thoughts on the rise of digital health High function meets low fidelity experience Room for both telehealth and in-person experiences [21:43 - 23:08] Closing Segment Let's talk five to seven years out  Low fidelity experience moving out of the office and into telehealth Real-time precision insights  Making the lab and insights experience open to everyone via mobile Technology is outpacing the health machine complex We're all in this together The introduction of utilizing people's information Final Words  Tweetable Quotes: “My diagnosis was really the aha moment for me when I really thought about how I could not only manage the condition better myself, but potentially help millions of other people manage it.” - Jeff Dachis “We're bringing data and information and insights to people in a way that allows them to act on their day to day biometric telemetry in ways that no other platform really can do.” - Jeff Dachis “We need a whole person solution, not a silo based solution.” - Jeff Dachis Connect with Jeff on https://www.linkedin.com/in/jeffreydachis/ (LinkedIn). Go check out the award winning app at https://onedrop.today/ (https://onedrop.today/).  To know more, you can connect with me, David Kliff onhttps://www.linkedin.com/in/ephraim-glick-8403a465/ ( )https://www.facebook.com/DiabeticInvestor/ (Facebook), https://twitter.com/diabetic_invstr?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor (Twitter), and https://www.linkedin.com/in/david-kliff-78b669b/ (LinkedIn), or email me at dkliff@diabeticinvestor.com. Be sure to visit https://diabeticinvestor.com (https://diabeticinvestor.com) for more insights and real-time analyses on the evolving business of diabetes. Don't be shy, I'd love to hear from you! You can also reach me at 224-715-3761. NOTE*: We are in no way a replacement for real medical professionals. All information in this podcast is obtained through reliable sources. Please be aware of our...

Technological advancements in healthcare have gone a long way, especially for glucose monitoring. In this episode, I talk to Kevin Sayer, the CEO of Dexcom, a glucose monitoring technology company. Kevin shares his thoughts on the current dynamics of digital diabetes and the sensory industry. He also talks about what he considers in choosing partnerships for his company and his thoughts on the future of glucose sensors.  I'm thrilled to have Kevin on the show. Join us and listen in!  [00:01 - 05:50] Opening Segment I introduce Kevin to the show Joining Dexcom Becoming CEO of the company Kevin's vision when he assumed the position [05:51 - 24:06]  Current Dynamics of the Sensor Industry How the sensor business has changed Advancements on different sensor types New features on mobile phones Dealing with various phone brands/types What Kevin thinks about Apple going into the healthcare industry Dexcom's relationship with other companies What he considers in choosing partnerships Kevin on the future of glucose sensors [24:07 - 30:24] Talking Market Competition  Kevin's thoughts on the company's market competition What keeps him up at night Dexcom's G7 sensor Jumping from G6 to G7 [30:25 - 34:47] The Future of Digital Diabetes  Digital Diabetes 5 years from now Kevin on his future with Dexcom [34:48 - 37:24] Closing Segment Kevin's advice to startups and young executives Tweetable Quotes: “Anything that makes the experience easier for people is what will keep me awake at night… It's gotta have something that people can rely on, and it has to be an experience that trumps what we can create.” - Kevin Sayer on competition  “What problem are you solving? People look at our business and say ‘Look at Dexcom's valuation, I'm going to make another sensor', and if I were gonna go do that, I'm asking myself the question: What am I going to do better than they do? Because you have to do something better.” - Kevin Sayer on his advice to young executives in the industry Connect with Kevin on https://www.linkedin.com/in/kevin-sayer-20b53715/ (LinkedIn). Go check out https://www.dexcom.com/home (https://www.dexcom.com/home) to learn more about Dexcom's glucose monitoring technology.  To know more, you can connect with me, David Kliff onhttps://www.linkedin.com/in/ephraim-glick-8403a465/ ( )https://www.facebook.com/DiabeticInvestor/ (Facebook), https://twitter.com/diabetic_invstr?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor (Twitter), and https://www.linkedin.com/in/david-kliff-78b669b/ (LinkedIn), or email me at dkliff@diabeticinvestor.com. Be sure to visit https://diabeticinvestor.com (https://diabeticinvestor.com) for more insights and real-time analyses on the evolving business of diabetes. Don't be shy, I'd love to hear from you! You can also reach me at 224-715-3761. NOTE*: We are in no way a replacement for real medical professionals. All information in this podcast is obtained through reliable sources. Please be aware of our https://diabeticinvestor.com/investment-newsletter-disclaimer/ (Disclaimer). LEAVE, SUBSCRIBE, REVIEW + help someone who wants to learn more about the wacky world of diabetes and everything happening within it. 

When it comes to diabetes tech, it's the results that speak louder than algorithms. Results driven and starting his career in high-tech, John Sheridan became an authority on tech start-ups leading him to his COO and leader CEO position in Tandem Diabetes Care. His strength has been in leading the commercialization of complex technologies, building the organizations and systems to support business objectives, and predictably delivering financial results. John is all about the patient and the positive experience they're left with. As a leader in diabetes technological innovation, I'm excited to learn from John as the CEO of Tandem Diabetes Care talks tech. [00:01 - 02:49] Opening Segment I introduce John Sheridan Some background on John's story Starting in high-tech  Working for start-ups  Joining Tandem as a COO All about the patient [02:50 - 13:11]  CEO of Tandem Diabetes Care Talks Tech John talks about the user interface of the T-slim Intuitive and easy to use In depth human factors testing  Projections on future dynamics on pumps  Seeing the benefits of Control IQ  Building systems around the pump  Improving user experience Going beyond the algorithm Algorithm is important, results are more important  Current goals and improvements [13:12 - 18:49] Navigating Market Competition  John talks about T-Sport  The difference from Control IQ Moving forward in convenience and discretion  Full mobile control  A response to Omnipod5 A competitive response  Size and aesthetic comparison  Having products that appeal to many  The opportunity for innovation in the market  Moving from pens and needles to a pump  [18:50 - 23:08] Closing Segment Let's talk five years out  Devices will still have a meaningful presence  Close but not quite fully set it and forget it  Quick technological advancements catching the attention of payers Talking about the Companion Acquisition  Tandem's future plans Thank you and please share this  Final Words  Tweetable Quotes: “I think you gotta look beyond the algorithm. The algorithm is important, but you gotta deliver the results.” - John Sheridan  “It's not gonna be this linear advancement of technology. We now have a portfolio of products that appeal to different people. Some people would prefer to continue to use a pump that has an interface on it, some would prefer to have mobile control; the smaller device.” - John Sheridan  “There's a number of opportunities that are similar to pens that are out there. I think that right now we're all about trying to increase the penetration rate in the MDI community; we think iteration is going to do that, and I think that pens are going to help.” - John Sheridan Connect with John on https://www.linkedin.com/in/john-sheridan-84302315/%5C (LinkedIn). Go check out https://www.tandemdiabetes.com/ (https://www.tandemdiabetes.com/) to learn more about this leader in diabetes technology.  To know more, you can connect with me, David Kliff onhttps://www.linkedin.com/in/ephraim-glick-8403a465/ ( )https://www.facebook.com/DiabeticInvestor/ (Facebook), https://twitter.com/diabetic_invstr?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor (Twitter), and https://www.linkedin.com/in/david-kliff-78b669b/ (LinkedIn), or email me at dkliff@diabeticinvestor.com. Be sure to visit https://diabeticinvestor.com (https://diabeticinvestor.com) for more insights and real-time analyses on the evolving business of diabetes. Don't be shy, I'd love to hear from you! You can also reach me at 224-715-3761. NOTE*: We are in no way a replacement for real medical professionals. All information in this podcast is obtained through reliable sources. Please be aware of our https://diabeticinvestor.com/investment-newsletter-disclaimer/ (Disclaimer). LEAVE, SUBSCRIBE,...

Diagnosed with Type 1 diabetes at seven months old, doctors told him he would likely be blind or dead before the age of 25. Phil Southerland is still here - healthy, thriving and committed to improving the lives of people affected by diabetes around the world. Phil is a global ambassador for diabetes and is committed to educating and empowering the 1.2 billion people across the globe associated with the condition. He serves as the CEO and Co-Founder of Team Novo Nordisk, and the CEO of Supersapiens. He built the world's first all-diabetes pro cycling team that aims to inspire, educate and empower everyone affected by diabetes. This will be a treat for sure. Tune in and learn from Phil how he earned respect for diabetes in the sporting world and how hard work and digital technology led the way. [00:01 - 08:27] Opening Segment I introduce Phil Southerland Some background on Phil's story Diagnosed at seven months old  A link between glucose and winning Starting into cycling  College life - getting a business plan  The first business and first investor  Getting into the bike industry  First cross-country biker with diabetes [08:28 - 17:28]  Earning Respect for Diabetes in the sporting World Phil talks about his team and the reaction from non-diabetics Earning for the respect of the peloton  Getting to an all-diabetes team  The approval process of various digital tools  Getting business outside of diabetes Even non-diabetics invested in the sensors  Respect for the work of CGM and other companies [17:29 - 29:07] Impacting the Sportsworld Even Outside of Diabetes Phil talks about the future of CGM  It affects everyone, even non-diabetics What we've begun to learn from the data set  Sometimes a functional pancreas isn't enough  The people included in Supersapiens  All the different athletes involved  The education strategy  How diet and exercise affects an athlete's glucose  Examples  [29:08 - 39:36] Closing Segment Phil talks about reaching all groups  People who aren't motivated  Giving people the lightswitch  Phil shares about his charity work  Work in Rwanda  Work in Macedonia  Partnerships that led to impact What's next for Phil  Impact diabetes and the sporting world  Putting CGM technology on athletes  Pathing the way for the developing world Thank you and please share this  Final Words  Tweetable Quotes: “Within a week of competing in sport I figured out two things - if I had good control of my glucose I could win, and if I did not have good control of my glucose I would fail.” - Phil Southerland “I want in the next 10 years, that we can make CGM so broadly accessible, so broadly accepted, adapted, and just such a core part of life, that we've brought CGM technology to people in the developing world…” - Phil Southerland Resources Mentioned:  https://www.supersapiens.com/en-EN/ (Supersapiens) Connect with Phill on https://www.linkedin.com/in/psoutherland/ (LinkedIn) and https://twitter.com/philsoutherland?lang=en (Twitter). Go to https://www.teamnovonordisk.com/ (https://www.teamnovonordisk.com/) to learn more about the team that's changing diabetes.  To know more, you can connect with me, David Kliff onhttps://www.linkedin.com/in/ephraim-glick-8403a465/ ( )https://www.facebook.com/DiabeticInvestor/ (Facebook), https://twitter.com/diabetic_invstr?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor (Twitter), and https://www.linkedin.com/in/david-kliff-78b669b/ (LinkedIn), or email me at dkliff@diabeticinvestor.com. Be sure to visit https://diabeticinvestor.com (https://diabeticinvestor.com) for more insights and real-time analyses on the evolving business of diabetes. Don't be shy, I'd love to hear from you! You can also reach me at 224-715-3761. NOTE*: We are in no...

The ones who impact diabetes are the ones who can meet people where they're at, and help them make better, informed decisions. One such person is Nadia Al-Samarrie, the Founder and Editor-in-Chief of Diabetes Health. Her AskNadia column is ranked #1 by Google and her DiabetesHealth website was named “Best Diabetes Blog” for 2019 & 2017 by Healthline. Nadia's efforts have made her stand out as a pioneer and leading patient advocate in the diabetes community. She is also an author of several books and has been featured on ABC, NBC, CBS, and other major cable networks. I'm looking forward to hearing from someone so impactful in the diabetes community.  [00:01 - 06:01] Opening Segment I introduce Nadia Al-Samarrie Some background on Nadia Getting into the business - Sugar Happy and DiabetesHealth Starting a radio show with live questions about diabetes Timeline and experience  A quick look at the rich history of the diabetes industry Nadia's experience in dealing directly with diabetes Family history  Understanding the overwhelm Picking people up where they're at [06:02 - 13:39]  How Publication Can Inspire Proactivity in the Diabetes Community Nadia shares about her book From Baghdad to Berkeley and the inspiration around it Timely for today's political landscape Her experience moving to a new country and culture  Inspiration for young and proactive woman  Background about Sugar Happy The inspiration for the book How to communicate with doctors  A practical guide - answering questions all newly diagnosed people have Nadia's experience with changes in patient engagement  Noticing people need another opinion With the advent of the internet…  [13:40 - 22:17] Patient Engagement and the Changing Industry Nadia's insights on patients with digital diabetes Patients going it alone and through support groups  Not everyone is comfortable with digitizing Nadia talks about proactivity among the T1D community  Some people act but most just want support  The hardest things as a publisher  Nadia's thoughts on what the industry will look like in 5 years Streamlined and automated systems Up and coming company - Kaiser Looking at other publications [22:18 - 28:59] Closing Segment Nadia talks about her future plans  Another book coming  Sugar Happy series  Giving people healthy recipes Helping people get a game plan Where you can find Nadia's content Links Below How Nadia can work with your team Resources available  What Nadia brings to the table Thank you and please share this  Final Words  Tweetable Quotes: “My job as a publisher is to take people and pick them up where they are - A to distil complicated information so they can understand it to make better decisions for themselves, and B to inspire them and ‘create the change' and let them know that they're not alone…” - Nadia Al-Samarrie “It's not always easy for people. I think what people look for is support, they look for talking with people, to get answers - not just doing some formulary documentation like some admin task.” - Nadia Al-Samarrie Resources Mentioned:  https://www.amazon.com/gp/product/B086VR58KS/ref=dbs_a_def_rwt_bibl_vppi_i0 (Sugar Happy) https://www.amazon.com/Baghdad-Berkeley-Womans-Affair-ebook/dp/B08GKFC593/ref=sr_1_1?dchild=1&keywords=baghdad+to+berkeley&qid=1620825160&s=digital-text&sr=1-1 (From Baghdad to Berkeley) https://podcasts.apple.com/za/podcast/diabetes-health-in-the-news-podcast/id1450764207 (Diabetes Health Podcast) Connect with Nadia on https://www.linkedin.com/in/nadia-al-samarrie-766214a/ (LinkedIn) and  https://www.instagram.com/asknadia_diabetes_health/?hl=en (Instagram). Go to https://www.diabeteshealth.com/ (https://www.diabeteshealth.com/) to start making a difference in your diabetes journey. To know more, you can connect with...

You guys are in for a treat today. I'm excited to have three giants of the diabetes industry here today to share their insights: Dr. Satish Garg, Dr. Irl Hirsch, and Dr. Steven Edelman. These men need no introduction, but in case you're in the 1% of people who don't know these gentlemen, do a bit of research and come back here when you're done. They are absolutely revolutionary in the world of diabetes devices, investment, and research. So I'm not going to do any fluff today, we're going to dive right into the real talk.  Come be a fly on the wall of this conversation, and join me in learning more about what is impacting the future of diabetes, what we should be excited about, and what we should be looking out for. [00:01 - 06:04] Opening Segment I introduce Satish, Irl, and Dr. Edelman Starting questions Satish talks first about what is currently exciting him in diabetes Devices widely accepted by the patients Companies are improving  Elimination on CGM  Irl follows up with his insights and excitement  Agreeing with Satish  Type 1 and Type 2 penetration The projections of the adolescent generation  Taking a bite out of obesity - game changer  Steven shares what he is currently excited about  Opening up to more screening  [06:05 - 16:01] Golden Insights from the Big 3 Satish talks about the issue of access  Who can afford these things Irl talks about the problem he sees with payers No concern around heart disease A fight for every drug  Satish's thoughts on telehealth What the Covid Pandemic has taught us  Plusses and minuses of telehealth  Irl's thoughts on ‘digital diabetes' ‘It's possible, but you need to show me' Would not invest just yet  Digital apps need to be standardized  There can't be 20 different forms  Everybody has a different approach  [16:05 - 25:00] What is Impacting the Future of Diabetes Satish talks about what he sees happening with patients The example of the creation of the term insulin resistance Why these apps don't work  Nothing replaces communication Nothing works long term that is robust yet The role of social media on diabetes today The issue of misinformation Satish talks about the drugs he likes for each type of diabetes T1 - CGM T2 - GLP Irl talks about what he is looking forward to for the future  T1 - Artificial pancreas  T2 - Zipa Tide Steven's desired outcome for the future T1 - Everyone having access to insulin for both want and need T2 - GLP  [25:01 - 33:32] Closing Segment I get the guys' perspective on a closed-loop system Satish: There are decent insulins that can achieve a decent glucose control Steven: If there is a liquid form, it would work better; insights on rapid-acting Satish: Holistic approach to make an impact  Irl: Too many people driving the ship; dependent on the need for glycemic control The importance of the impact on pregnancy  Focussing on the US Clear message to the industry Start talking to each other, and start thinking about the patients Make the drug too expensive, and only a few will pay for it A lot of money wasted on ‘Me-Too drugs' - lower the price and still profit Thank you and please share this  Final Words  Tweetable Quotes: “If I see someone using a meter, I throw their meter in the trash can and give them a new sensor from the clinic, that's all they're gonna do, and there's not a single patient… who hasn't said, ‘this has changed my life.'” - Dr. Satish Garg “This is a game-changer, so just like insulin, the haves and the have nots - who's going to have access to all these amazing drugs that science has come up with? That to me is the big question.” - Dr. Irl Hirsch   “One reason why these apps don't work is that patients need to have their doctors… nothing replaces communication. Between our broken health care system and the short...

Having both his daughters diagnosed with T1D, David Panzirer decided it was his calling to spring into action and change the wacky world of diabetes for the better. David became a full-time trustee of Helmsley Charitable Trust, a trust that partners with grantees and funders that move the powers-at-be to improve the lives of others. His goal is to intervene and impact the management process of this disease for those who live with it by working on the tools and care modules they use. Let's jump right into the episode and learn from David how he is easing the burden of those living with T1D. [00:01 - 02:49] Opening Segment I introduce David Pnazirer to the show Helmsley Trust David gives some background around his story Oldest daughter (17) diagnosed with diabetes first Became a trustee with Helmsley - $7B Trust Second daughter diagnosed at age 14 David's mission and work Stop diabetes before you ever have autoimmunity  Primary prevention  Screening newborns for genetic risk Drug discovery Improving the lives of those with T1D [02:50 - 13:44] Easing the Burden of Those Living with T1D David talks about the optimistic outlook The innovations in technology from years ago to now  Reliable CGM  Automated insulin delivery Taking diabetes data and making it actionable David talks about current frustrations  Academic Silos in research Wishing processes would go faster  FDA needs to take the perspective of the patient David's stance on Human Involved System vs. Split model  In the middle  Autopilot is 90% but you can never have a human step out  The role of social media in diabetes management  A vocal minority vs. the silent majority  Projecting the impact from 5 years today 5 years ago would have been CGM's 5 years later will involve algorithm and automated systems DreaMed Things will only get better [13:45 - 18:22] Closing Segment David's stance on a ‘good enough' algorithm Life happens  Insulin companies beat up in the media The fear of Insulin's inability to innovate David talks about his current space Currently in the insulin space How to reach out and support David Always asking is this the best way to use every dollar? Turning one dollar into five Links below Thank you and please share this  Final Words  Tweetable Quotes: “I don't know of another disease where the patient and caregiver are making dosing decisions with a drug that could kill them, they make those decisions 24/7, and if they get it right 60% of the time they're doing amazing…” - David Panzirer “People call it artificial intelligence or decisions report, I call it - take all my diabetes data and make it into something actionable.” - David Panzirer “I do think as I tell my kids… what you do right now is the worst it's ever going to be for you, and it's only going to get better from here, and I wholeheartedly believe that.” - David Panzirer Resources Mentioned:  https://dreamed-diabetes.com/ (DreaMed AI) Connect with David on https://twitter.com/dpt1d?lang=en (Twitter). Visit https://helmsleytrust.org/ (https://helmsleytrust.org/) to learn more about supporting the space that's trying to impact the lives of others. To know more, you can connect with me, David Kliff onhttps://www.linkedin.com/in/ephraim-glick-8403a465/ ( )https://www.facebook.com/DiabeticInvestor/ (Facebook), https://twitter.com/diabetic_invstr?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor (Twitter), and https://www.linkedin.com/in/david-kliff-78b669b/ (LinkedIn), or email me at dkliff@diabeticinvestor.com. Be sure to visit https://diabeticinvestor.com (https://diabeticinvestor.com) for more insights and real-time analyses on the evolving business of diabetes. Don't be shy, I'd love to hear from you! You can also reach me at 224-715-3761. NOTE*: We are in no way a replacement for real medical professionals. All information in this podcast...

Today we're doing a deep dive on the devices to look out for in the market, with expert Erik Verhoef. Erik founded Seagrove Partners in 2016 after spending 9 years at Tandem Diabetes Care (NASDAQ: TNDM), where he headed up Strategy, Business Development, Marketing and Market Research, leading to the design and commercial launch of t:slim, the award-winning insulin pump. He played a pivotal role in the core team that completed Tandem's initial public offering — one of the most successful issuances in medical device history. Erik started his career in healthcare consulting at Tiber Group, Campbell Alliance, and the Advisory Board Company.   With that impressive resume, let's really tune in and learn more from Erik about the today and tomorrow of diabetes devices and what to look out for in the market. [00:01 - 02:22] Opening Segment I introduce Erik Verhoef to the show CEO and President of Seagrove Partners  Erik gives a bit of background on himself In the industry for 30+ years  The journey his career took  The start and activities behind Seagrove Partners Erik's current activities  Oncology and diabetes  Device focussed  [02:23 - 11:41] The Today and Tomorrow of Diabetes Devices Erik talks about his involvement with the newest Pens Erik's perspective on the next 5 years The Type 1 side  On the Pump side The Type 2 side The difference between us and the international markets The HGH expenses in America Spotty when it comes to CGM and Pumps The reimbursement deal Scandanavian companies seem to be more progressive The progressiveness in Pediatrics  The low points of Eastern Europe Erik's thoughts on wearable devices  What problem are you trying to solve?  [11:42 - 21:30] Biggest Players in the Industry Erik's thoughts on Medtronic Centres  Not over-promising  Coming back as a growth players Comparing their integrations Stand-alone CGM market Smart acquisitions with Companion Opinions around Sport Pump from Tandem Coming out of focus groups from 2009  Choosing the right size and cartridge  Playing with the idea of phone control  Closed-loop performance Eli Lilly getting in the pump market Large European footprint  Their plan to get into the pump industry  Compared to companies like Novo Erik talks about who the top players will be post-covid What companies have to do get there  The companies that currently have these pieces  [22:31 - 28:02] Differentiations in the Market Thoughts on other upcoming devices  What differentiates it  Not seeing the market for a lot of up and comers  Erik talks about the staying power of Apple  Making their tech actionable, interactive, and easy  Erik's insights on what will break through the market  Oral Insulin  Israel - in phase 3 currently  Current studies [28:03 - 33:09] Closing Segment Erik shares his final thoughts on game-changers in the market  Insulin from Novo Innovators in CGM  Erik talks about the studies that he publishes Two major primary research studies a year What it covers  Partnering with Beyond Type 1 How to reach out to Erik Links below Thank you and please share this  Final Words  Tweetable Quotes: “I think that the pace of innovation in Type 2 has been good… Now I think we're at this tipping point…” - Erik Verhoef  “When everybody talks about their closed-loop system performance, it's time in closed-loop. So why would you want people to disconnect from your pump if you're going for that argument that you should always be in closed-loop?” - Erik Verhoef  “[On up and coming devices] The question is what differentiates it from the other ones? They're all gonna have some kind of, Bolus Wizard, or Data Count Cards… How easy do you make it for people to follow you…?” - Erik Verhoef “If you can have these...

The companies that are tied around the voice of the patients are the ones that win. This is the belief of our very first interviewee, Davide Edelman. David is the Founder and CEO of Thrivable. He is an entrepreneur, author, speaker, advocate, and generally loves all things ‘learning.' If you don't know, Thrivable is a startup that helps health care companies get the voice of their patients into all their decision making. Through his work, he connects people to the community, partnership, and education as well as patients to organizations. With all the incredible things David does for the diabetes community, I'm excited to dive in and talk about how David took companies from surviving on basic research to Thrivable. [00:01 - 02:10] Opening Segment I introduce David Edelman to the show CEO of Thrivable  David gives a bit of background on himself Family background Self-proclaimed Lifelong Geek - involved in tech Introduced to the world of diabetes already as an entrepreneur Not much out there as far as information Created Diabetes Daily  A community of support [02:11 - 07:50] The Changes in the Diabetes Industry David talks through the changes he's seen in the industry within 16 years The rise of social media and information consumption The rise of consumer electronics Designing the customer experience A change in the dialogue  Pulling out to a ‘Beginner Perspective' Dealing with the burnout and anxiety More interest and engagement than ever  [07:51 - 17:57] Creating a Thrivable Company  David shares his story creating Thrivable  Working with advertisers  A need for patients to have their voices heard The building process and model Responsiveness to the market  We have to be more responsive The more patient-centric companies win The legacy of healthcare in this space Top complaints from patients The complaints around certain drugs  Many complaints around access to health care  How patients are feeling today A cause for optimism  The rise of tech and accessibility  Transformative technology  David shares about his experience during Covid Tools from the doctor to monitor Health  We can be our own doctors at home  [17:58 - 21:59] Creating a Thrivable Community David shares about decisions around customer requests and needs Examples  David talks about the projection of his company The ‘why' trail Co-creation  Creating Communities that lead to progress [22:00 - 26:26] Closing Segment Your perfect 5-year scenario? 5-year change vs. 25-year change Faith in the engineering side  How to reach out to David Links below Thank you and please share this  Final Words  Tweetable Quotes: “We've been helping these companies get a ‘real-time patient voice,' into their organization… What do patients actually think about these decisions we have to make?” - David Edelman “The companies that are more tied around the patient's needs are the ones that are winning.” - David Edelman Resources Mentioned: https://www.diabetesdaily.com/ (Diabetes Daily) https://www.amazon.com/Thriving-Diabetes-Lifelong-Featuring-Long-Lasting/dp/1592336779 (Thriving with Diabetes - David Edelman) Connect with David on https://www.linkedin.com/in/davidedelman/ (LinkedIn) and https://twitter.com/davidtalk?lang=en (Twitter), or david@thrivable.app. Be sure to visit https://thrivable.app/ (https://thrivable.app/) to learn more about becoming part of this community.  To know more, you can connect with me, David Kliff onhttps://www.linkedin.com/in/ephraim-glick-8403a465/ ( )https://www.facebook.com/DiabeticInvestor/ (Facebook), https://twitter.com/diabetic_invstr?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor (Twitter), and https://www.linkedin.com/in/david-kliff-78b669b/ (LinkedIn), or email me at dkliff@diabeticinvestor.com. Be sure to visit https://diabeticinvestor.com...

Audiogram Segment: 3:07 - 3:27 (beginning) This change… (end) For all the diabetes device companies. Welcome back to The Wacky World of Diabetes Podcast. Everyone knows by now that Covid has significantly changed our world in so many ways, and the world of Diabetes is no different. Now more than ever, we have seen a huge rise in the virtualization of patient support and digital diabetes. However, from an investment standpoint, I believe I have some insights for you about the changes in diabetes products, and the projected usage of digital diabetes, that may surprise you. Be sure to dive straight in this episode and let's explore some of the changes we've seen from Covid, and how the future of diabetes products is changing, for what I believe, is the better. [00:01 - 05:19] Opening Segment ● Welcome to the second episode ○ Reminder of the disclaimer ■ Links below ● Covid19 has made for a lot of changes ○ How Covid helped along digital health ○ A change in training for devices ○ How it affects major device companies ■ Cost effective training methods ○ Virtualizing patient support ○ A Net Positive for device companies ○ When Covid is under control [05:20 - 14:52] The Future of Digital Devices and Changes in the Product Landscape ● I talk about my insights on the change in digital usage ○ Not a standard but an adjunct ○ People still want to see their doctors ○ I believe digital will not stay on the forefront ● What will happen to the digital space ○ I believe it is overvalued ○ The day of reckoning ○ The effect of additional competition ● Sales for device company ○ Lowered costs ● Projection of upcoming health care stats ○ Looking at drug pricing and device pricing ○ Something will be done but uncertain of what ○ Movement being made on the Affordable Care Act ○ What we don't know yet ● Positive changes to come during 2020 ○ Medtronic acquiring companion medical ○ Underestimated event that will impact sales ○ The Combo GIP and GP1 product ○ Who has the edge now? [14:53 - 16:45] Closing Segment ● Summarizing the significant events people missed in 2020 ● We are making progress ○ Life will get back to some kind of normal ● 2022 is when we'll really know what a post-covid world looks like ● Happy Holidays to everyone! ● Thank you and please share this ● Final Words Tweetable Quotes: “This change, going through what I call a virtualization of patient training and patient support, was going to come out anyways, but because of Covid, it accelerated that move and in the end I view this as a net positive…” - David Kliff “I'm probably one of the few, quite honestly, who is not convinced that digital diabetes, in particular, will remain on the forefront or have solid long term value from an investment standpoint.” - David Kliff To know more, you can connect with me, David Kliff on Facebook, Twitter, and LinkedIn, or email me at dkliff@diabeticinvestor.com. Be sure to visit https://diabeticinvestor.com for more insights and real-time analyses on the evolving business of diabetes. Don't be shy, I'd love to hear from you! You can also reach me at 224-715-3761. NOTE*: We are in no way a replacement for real medical professionals. All information in this podcast is obtained through reliable sources. Please be aware of our Disclaimer. LEAVE, SUBSCRIBE, REVIEW + help someone who wants to learn more about the wacky world of diabetes and everything happening within it.

Listen this is our first podcast ever so seriously no expectations we're still in the learning phase but promise we'll get better as we go along